[{"id":"917c0cc6-62ef-4f4e-a9b8-4b4d7481e702","acronym":"","url":"https://clinicaltrials.gov/study/NCT03369964","created_at":"2021-01-18T16:37:54.009Z","updated_at":"2024-07-02T16:37:11.798Z","phase":"Phase 1","brief_title":"A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03369964","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Gazyva (obinutuzumab) • emactuzumab (RG7155)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/14/2018","start_date":" 03/14/2018","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 08/31/2019","study_completion_date":" 08/31/2019","last_update_posted":"2018-04-05"},{"id":"7a5d5274-188b-454f-a274-136cb9718498","acronym":"","url":"https://clinicaltrials.gov/study/NCT01494688","created_at":"2021-01-18T06:15:43.986Z","updated_at":"2024-07-02T16:37:12.988Z","phase":"Phase 1a/1b","brief_title":"A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT01494688","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD163 • CD68 • CSF1R","pipe":" | ","alterations":" CD163 expression","tags":["CD163 • CD68 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • emactuzumab (RG7155)"],"overall_status":"Completed","enrollment":" Enrollment 217","initiation":"Initiation: 12/20/2011","start_date":" 12/20/2011","primary_txt":" Primary completion: 02/07/2018","primary_completion_date":" 02/07/2018","study_txt":" Completion: 02/07/2018","study_completion_date":" 02/07/2018","last_update_posted":"2018-03-16"}]